Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema

Ophthalmology

Volumn 118, Issue 4, 2011, Pages

  Campochiaro, Peter A ^a   Brown, David M ^b   Pearson, Andrew ^c   Ciulla, Thomas ^d   Boyer, David ^e   Holz, Frank G ^f   Tolentino, Michael ^g   Gupta, Amod ^h   Duarte, Lilianne ⁱ   Madreperla, Steven ^j   Gonder, John ^k   Kapik, Barry ^l   Billman, Kathleen ^l   Kane, Frances E ^l  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Vitreoretinal Consultants   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d MIDWEST EYE INSTITUTE   (United States)

^e RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^f UNIVERSITY OF BONN   (Germany)

^g Center for Retina and Macular Disease   (United States)

^h POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

ⁱ Associacao para a Investigacao Biomedica e Inovacao Em Luz e Imagem   (Portugal)

^j Retina Associates of New Jersey   (United States)

^k ST JOSEPH S HEALTH CENTRE   (Canada)

^l Alimera Sciences Limited   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; STEROID;

ADULT; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR PRESSURE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEROID THERAPY; TRABECULOPLASTY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79953329178     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.12.028     Document Type: Article

References (31)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003. (Pubitemid 28268322)
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
4. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-59.
5. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental inspired oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2003;45:617-24. (Pubitemid 38140522)
6. Ozaki H, Yu A, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-9. (Pubitemid 29029587)
7. Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003;93:1074-81. (Pubitemid 37485038)
8. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-9.
9. Nguyen QD, Shah SM, Heier JS, et al, READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-81.
10. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2010;117:2146-51.
11. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
12. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal Bevacizumab or Laser Therapy in the management of diabetic macular edema (BOLT Study): 12-month data: report 2. Ophthalmology 2010;117:1078-86.
13. Schroder A, Palinski W, Schmid-Schonbein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991;139:81-100.
14. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2. (Pubitemid 39561611)
15. Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 2007;21:3219-30.
16. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-15. (Pubitemid 28131129)
17. Machein MR, Kullmer J, Ronicke V, et al. Differential down-regulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999;25:104-12. (Pubitemid 29221760)
18. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003;44:1192-201. (Pubitemid 36297840)
19. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4. (Pubitemid 41685887)
20. Wang K, Wang Y, Gao L, et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008;31:1541-6.
21. Singhal S, Lawrence JM, Salt TE, et al. Triamcinolone attenuates macrophage/microglia accumulation associated with NMDA-induced RGC death and facilitates survival of Muller stem cell grafts. Exp Eye Res 2010;90:308-15.
22. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7. (Pubitemid 32768624)
23. Jonas JB, Kreissig I, Degenring R. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
24. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75. (Pubitemid 38849806)
25. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirtyfour-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7. (Pubitemid 43795240)
26. Campochiaro PA, Hafiz G, Shah SM, et al, Famous Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-9.
27. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995;113:1019-29.
28. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology 2007;114:1190-6.
29. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol 1992;110:188-95.
30. Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-33.
31. Haller JA, Kuppermann BD, Blumenkranz MS, et al, Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.